Drugs / Indantadol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01401673 | Oct 2009 → Aug 2010 | — | Vernalis (R&D) Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT00794430 | Dec 2008 → Dec 2009 | diabetic polyneuropathy | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00375960 | Jun 2006 → Apr 2007 | diabetic neuropathy | Vernalis (R&D) Ltd | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indantadol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01401673 ↗ |
| Known as | Chf-3381 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707400 ↗ |
| Known as | Chf3381 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707400 ↗ |
| Known as | V3381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00794430 ↗ |
| Action | Inhibit | “Monoamine oxidase A inhibitor” CHEMBL3707400 ↗ |
| Route | Oral | “Two Escalating, Oral Doses of V3381 (200 mg BID and 400 mg BID)” NCT00375960 ↗ |
| Target | MAOA | “Monoamine oxidase A inhibitor” CHEMBL3707400 ↗ |